Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
610
mi
from
Chicago, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Regional Health Center
486
mi
from
Mount Vernon, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Regional Health Center
486
mi
from
Mount Vernon, IL
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Community Cancer Center Foundation
510
mi
from
Normal, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Community Cancer Center Foundation
510
mi
from
Normal, IL
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Methodist Medical Center of Illinois
484
mi
from
Peoria, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Methodist Medical Center of Illinois
484
mi
from
Peoria, IL
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Medical Center
485
mi
from
Peoria, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Medical Center
485
mi
from
Peoria, IL
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University of Kentucky, Markey Cancer Center
725
mi
from
Lexington, KY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University of Kentucky, Markey Cancer Center
725
mi
from
Lexington, KY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Mary Mercy Hospital
827
mi
from
Livonia, MI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Mary Mercy Hospital
827
mi
from
Livonia, MI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Oakland
835
mi
from
Pontiac, MI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Oakland
835
mi
from
Pontiac, MI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
William Beaumont Hospital-Royal Oak
839
mi
from
Royal Oak, MI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
William Beaumont Hospital-Royal Oak
839
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
William Beaumont Hospital, Troy
843
mi
from
Troy, MI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
William Beaumont Hospital, Troy
843
mi
from
Troy, MI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology Hematology PA-Maplewood
559
mi
from
Maplewood, MN
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology Hematology PA-Maplewood
559
mi
from
Maplewood, MN
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
552
mi
from
Minneapolis, MN
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Health Partners Inc
552
mi
from
Minneapolis, MN
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Health Partners Inc
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology and Hematology PA-Woodbury
555
mi
from
Woodbury, MN
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology PA-Woodbury
555
mi
from
Woodbury, MN
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Freeman Health System
187
mi
from
Joplin, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Freeman Health System
187
mi
from
Joplin, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital-Joplin
189
mi
from
Joplin, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital-Joplin
189
mi
from
Joplin, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Liberty Radiation Oncology Center
210
mi
from
Liberty, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Liberty Radiation Oncology Center
210
mi
from
Liberty, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Louis Cancer and Breast Institute-South City
418
mi
from
Saint Louis, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Louis Cancer and Breast Institute-South City
418
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Saint Louis
405
mi
from
Saint Louis, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Saint Louis
405
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Cancer Research for the Ozarks NCORP
254
mi
from
Springfield, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Cancer Research for the Ozarks NCORP
254
mi
from
Springfield, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Cancer Care of Western North Carolina
857
mi
from
Asheville, NC
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Cancer Care of Western North Carolina
857
mi
from
Asheville, NC
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Mountain Radiation Oncology
857
mi
from
Asheville, NC
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Mountain Radiation Oncology
857
mi
from
Asheville, NC
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Summa Akron City Hospital/Cooper Cancer Center
899
mi
from
Akron, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Summa Akron City Hospital/Cooper Cancer Center
899
mi
from
Akron, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Mount Carmel Health Center West
809
mi
from
Columbus, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Mount Carmel Health Center West
809
mi
from
Columbus, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Providence Saint Vincent Medical Center
1388
mi
from
Portland, OR
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Providence Saint Vincent Medical Center
1388
mi
from
Portland, OR
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC-Heritage Valley Health System Beaver
957
mi
from
Beaver, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC-Heritage Valley Health System Beaver
957
mi
from
Beaver, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Presbyterian Hospital
974
mi
from
Pittsburgh, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Presbyterian Hospital
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Uniontown Hospital Radiation Oncology
984
mi
from
Uniontown, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Uniontown Hospital Radiation Oncology
984
mi
from
Uniontown, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Washington Hospital Radiation Oncology
957
mi
from
Washington, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Washington Hospital Radiation Oncology
957
mi
from
Washington, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Lankenau Medical Center
1220
mi
from
Wynnewood, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Lankenau Medical Center
1220
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
WellSpan Health-York Hospital
1142
mi
from
York, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
WellSpan Health-York Hospital
1142
mi
from
York, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Spartanburg Medical Center
903
mi
from
Spartanburg, SC
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Spartanburg Medical Center
903
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
345
mi
from
Dallas, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
345
mi
from
Dallas, TX
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
American Fork Hospital / Huntsman Intermountain Cancer Center
768
mi
from
American Fork, UT
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
American Fork Hospital / Huntsman Intermountain Cancer Center
768
mi
from
American Fork, UT
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Allan Blair Cancer Centre
938
mi
from
Regina,
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Allan Blair Cancer Centre
938
mi
from
Regina,
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Mills-Peninsula Medical Center
1339
mi
from
Burlingame, CA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Mills-Peninsula Medical Center
1339
mi
from
Burlingame, CA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Smilow Cancer Hospital Care Center at Saint Francis
1357
mi
from
Hartford, CT
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Smilow Cancer Hospital Care Center at Saint Francis
1357
mi
from
Hartford, CT
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Northeast Georgia Medical Center-Gainesville
817
mi
from
Gainesville, GA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Northeast Georgia Medical Center-Gainesville
817
mi
from
Gainesville, GA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Heartland Cancer Research NCORP
498
mi
from
Decatur, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Heartland Cancer Research NCORP
498
mi
from
Decatur, IL
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare - Galesburg
455
mi
from
Galesburg, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare - Galesburg
455
mi
from
Galesburg, IL
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
479
mi
from
Pekin, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
479
mi
from
Pekin, IL
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
485
mi
from
Peoria, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
485
mi
from
Peoria, IL
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Northwestern Medicine Cancer Center Warrenville
583
mi
from
Warrenville, IL
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Northwestern Medicine Cancer Center Warrenville
583
mi
from
Warrenville, IL
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Kansas City NCI Community Oncology Research Program
193
mi
from
Prairie Village, KA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Kansas City NCI Community Oncology Research Program
193
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Michigan Cancer Research Consortium NCORP
806
mi
from
Ann Arbor, MI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Michigan Cancer Research Consortium NCORP
806
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Beaumont Hospital-Dearborn
831
mi
from
Dearborn, MI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Beaumont Hospital-Dearborn
831
mi
from
Dearborn, MI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Lake Huron Medical Center
885
mi
from
Port Huron, MI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Lake Huron Medical Center
885
mi
from
Port Huron, MI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota Community Oncology Research Consortium
548
mi
from
Saint Louis Park, MN
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota Community Oncology Research Consortium
548
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
1288
mi
from
New York, NY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
1288
mi
from
New York, NY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
971
mi
from
Winston-Salem, NC
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
971
mi
from
Winston-Salem, NC
Click here to add this to my saved trials